贾威河可以通过抑制2组先天性淋巴细胞反应减轻过敏气道炎症
Yu Wang1, Jie Cui1, Yuwei Jiang1
1Institute of Respiratory Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Journal of ethnopharmacology
|February 19, 2024
概括
贾威阳河脱剂 (JWYHD) 通过抑制2型先天性淋巴细胞 (ILC2) 有效地减少了喘小鼠的呼吸道炎症. 这项研究提供了JWYHD的证据.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 贾威河 (Jiawei Yanghe Decoction,简称JWYHD) 是一种经过修改的草药配方,它显示出治疗喘等慢性炎症疾病的潜力.
- 没有完全理解JWYHD缓解过敏喘症状的确切机制.
- 在已建立的喘模型中,研究JWYHD的治疗效果和潜在机制至关重要.
研究的目的:
- 在过敏性喘的小鼠模型中评估JWYHD的治疗疗效.
- 阐明JWYHD发挥抗喘作用的分子机制.
- 在JWYHD中识别关键的分子标和活性化合物.
主要方法:
- 建立一个卵胺 (OVA) 诱导的过敏喘小鼠模型.
- 对JWYHD的管理和炎症标志物,细胞因子 (IL-4,IL-5,IL-13,IL-33,TNF-α),IgE和呼吸道过敏反应的评估.
- 使用UPLC-Q-TOF/MS进行化学分析,RNA-seq用于机制阐明,流细胞计和Smart-RNA-seq用于ILC2分析,以及分子对接用于目标验证.
主要成果:
- 在喘小鼠中,JWYHD显著降低了呼吸道炎症,炎症细胞透以及关键的促炎细胞因子和IgE水平.
- 通过减轻呼吸道过敏反应和肺组织损伤,JWYHD显示出保护作用.
- 机械研究表明,JWYHD抑制了2型先天性淋巴细胞 (ILC2) 反应,可能通过向Nrp1,GATA3和ST2,其活性化合物如利基酸和伊卡林显示出高结合亲和力.
结论:
- 在小鼠中,JWYHD对过敏性喘具有显著的治疗作用,主要是通过抑制ILC2-介导的炎症.
- 这些发现为JWYHD在喘管理中的临床使用提供了药理基础.
- 识别特定的分子标和活性化合物为进一步药物开发提供了途径.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
297
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
297
Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442


